Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Lexeo Therapeutics (LXEO) EBIAT (2022 - 2026)

Lexeo Therapeutics' EBIAT history spans 2 years, with the latest figure at -$14.2 million for Q4 2023.

  • On a quarterly basis, EBIAT rose 2.79% to -$14.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$66.4 million, a N/A change, with the full-year FY2025 number at -$100.0 million, down 1.7% from a year prior.
  • EBIAT hit -$14.2 million in Q4 2023 for Lexeo Therapeutics, up from -$20.1 million in the prior quarter.
  • Over the last five years, EBIAT for LXEO hit a ceiling of -$13.4 million in Q2 2023 and a floor of -$20.1 million in Q3 2023.